Endocrine Abstracts

Introduction: Acute hyperlipidemic pancreatitis is a rare clinical entity that usually affects patients with previous lipid alterations (triglyceride concentration >500 mg/dl) associated with triggering secondary factors, such as poorly controlled diabetes mellitus (DM).Clinical Case: We present the case of a 60-year-old man who came to the Emergency Department with a picture of acute abdominal pain secondary to acute pancreatitis in which a small hy...

Background: Previous studies of association between maternal thyroid autoimmunity and adverse pregnancy outcomes have produced inconsistent results.Objective: To examine whether thyroid autoimmunity detected at first trimester screening is predictive of a range of adverse obstetric and fetal outcomes.Patients and methods: We studied 438 women with singleton pregnancies who underwent first trimester screening test between June and J...

Introduction: Immune checkpoint inhibitors (ICIs) are a type of immunotherapy approved for the treatment of certain tumors. As the use of ICIs increases, the incidence of rare side effects, called immune-related adverse effects (IRAE), is also increasing, and can affect different systems (gastrointestinal, hepatic, and endocrine among others), with hyponatremia being a possible side effect in patients treated with ICIs. Our objective is to describe one of the few clinical case...

IntroductionUp by 30% of patients have recurrence in the first years after treatment of differentiated thyroid cancer (DTC) so it is necessary to have highly sensitive assays that allow adequate long-term follow-up. Nowadays, the measurement of serum thyroglobulin (Tg) is used as a tumor marker to monitoring DTC and must be determined along with levels of antithyroglobulin antibodies, since they can interfere in Tg immunoassays. Therefore, it is recommen...

Introduction: Immunotherapy is the oncological treatment whose objective seeks, through the use of immunomodulatory monoclonal antibodies, to block the regulation of the activation and response of T cells, increasing their antitumor response. Pembrolizumab is a new monoclonal antibody directed against the surface protein PD 1, (Programmed Cell Death-1), responsible for the inhibition of the immune response, mediated by T cells, against cancer cells; indicated in the treatment ...